August 17, 2020
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the introduction of OmniWire, the world’s first solid core pressure wire for coronary artery interventional procedures. With its breakthrough solid core construction, physicians can more easily maneuver the wire in the patient’s circulatory system to measure blood pressure along the vessel and guide the delivery of catheters and stents. The new wire supports iFR (instant wave-Free Ratio) measurements, the only resting index supported by randomized controlled outcome trials [1-3], as well as FFR (fractional flow reserve) measurements. It also integrates with the Philips IntraSight interventional applications platform, which can co-register iFR data onto the angiogram (interventional X-ray image) to precisely identify the parts of vessels requiring treatment.
Traditional pressure wires use a hollow metal tube (hypotube) to house the wiring that transmits the pressure information. Due to their thin walls, these wires can be challenging to maneuver and can sometimes kink, potentially becoming damaged during the procedure. OmniWire is the world’s first solid core pressure guidewire, using advanced conductive ribbons embedded in its outer polymer layer to communicate pressure information. The front (distal) part of the wire is made from Nitinol, a super-elastic, durable material that is commonly used in non-diagnostic, interventional ‘workhorse’ guide wires. The back (proximal) part of the wire is constructed from a high-strength cobalt alloy that provides the high durability required for complex and multi-vessel cases.
“I have been very impressed with the handling of OmniWire, the new solid core design performed beautifully, and I was able to navigate the difficult case easily,” said Dr. Jasvindar Singh, director of the catheterization lab at Barnes Jewish Hospital and associate professor at Washington University in St. Louis, U.S., who performed the first human case with OmniWire in the country. “We used iFR co-registration and found that the patient needed a stent. I was then able to perform the whole procedure working over OmniWire. This is truly an innovation in percutaneous coronary interventions.”
The new wire supports both iFR and FFR indices. iFR continues to be adopted into clinical practice and has been validated in clinical outcomes studies with data from over 4,500 patients [1,2] as well as being recognized by the European Society of Cardiology (ESC), the Society for Cardiovascular Angiography and Interventions (SCAI) and the American College of Cardiology (ACC) [4-6].
OmniWire integrates with IntraSight, Philips’ secure interventional applications platform that integrates a comprehensive suite of clinically proven modalities including iFR, FFR, IVUS (intravascular ultrasound) and co-registration  to simplify complex interventions and speed routine procedures. With iFR pullback and co-registration, physicians can identify the precise locations causing ischemia, plan stent length and placement with a virtual stent, and predict physiologic improvement.
“With integration and co-registration on our IntraSight platform, measurement with iFR, and now enhanced wire performance thanks to OmniWire, we’re providing clinicians with an advanced solution at every step of the procedure,” said Chris Landon, Senior Vice President and General Manager Image Guided Therapy Devices, Philips. “Physicians can confidently use a functional guidance strategy across all their patients, including in complex and multi-vessel cases. Today’s announcement demonstrates how our unique portfolio of systems, smart devices, software and services combines to deliver advanced procedure-oriented solutions.”
OmniWire is now available in the U.S. and Japan and has received clearance from the U.S. Food and Drug Administration (FDA) and approval from the Japan Pharmaceuticals and Medical Devices Agency. For more information, visit philips.com/OmniWire.
 Davies JE, et al., Use of the Instantaneous Wave-free Ratio or Fractional Flow Reserve in PCI. N Engl J Med. 2017 May 11;376(19):1824-1834.
 Gotberg M, et al., iFR-SWEDEHEART Investigators. Instantaneous Wave-free Ratio versus Fractional Flow Reserve to Guide PCI. N Engl J Med. 2017 May 11;376(19):1813-1823.
 Jeremias A, et al. Blinded physiological assessment of residual ischemia after successful angiographic percutaneous coronary intervention. The DEFINE PCI study. J Am Coll Cardiol Intv 2019;12:1991–2001.
 2018 ESC/EACTS Guidelines on myocardial revascularization: The task force on myocardial revascularization of the European society of cardiology (ESC) and European association for cardio-thoracic surgery (EACTS). Eur Heart J. 2018;00:1-96.
 Lofti A, et al. Focused update of expert consensus statement: Use of invasive assessments of coronary physiology and structure: A position statement of the society of cardiac angiography and interventions. Catheter Cardiovasc Interv. 2018;1–12.
 ACC-SCAI recommendation letter for Volcano iFR CPT coding (93571, 93572).
 Co-registration tools available within IntraSight 7 configuration via SyncVision.
For further information, please contact:
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 81,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.